Company intelligence / Profile preview

RetinAI Medical

Bern, Switzerland

Ownership: Private
Employees: ~28
Development stage: Other

Overview

RetinAI provides AI-powered cloud software for real-time analysis of ophthalmology images, supporting automated evaluation, segmentation, and quantification of clinical biomarkers in retinal diseases. It is certified as a Class IIa medical device under EU-MDR with clinical-grade AI modules available for research and healthcare customers.[2][4][1]

Therapeutic areas: Ophthalmology
Modalities: DeviceNon-pharmacological therapySoftware
Industry: Medical Imaging

Partnerships

SanoptisIkerian AGVarious pharmaceutical companies (unspecified)

Beyond the preview

Go deeper on RetinAI Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RetinAI Medical.

Explore the full profile